
Xcelience, LLC
Advertisement
Articles by Xcelience, LLC


Sponsored Content
When the clinical protocol dictates and/or helps with patient compliance, it can be necessary for investigational drug products to be packaged in blinded blister cards (wallets) that contain two, or more, different strength products. The presence of different products (placebo and/or active strengths) inside a packaging suite clearly raises the potential for error. So to combat this, a whole series of physical segregation and process controls are put in place to act as safeguards against product mix-ups.
Advertisement
Latest Updated Articles
Considerations in the Development of Controlled Release FormulationsSeptember 1st 2015
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Why Big Pharma Is Betting Billions on Protein Degraders for Cancer
2
Enhancing Clinical Data Infrastructure for AI Research: A Strategic Guide for Pharma Professionals
3
CPHI Americas: The Business Case for Product Carbon Footprints in Pharma
4
Investigating Patient Complaints About Combination Products
5